Management of heavy menstrual bleeding: Is hysterectomy the radical mastectomy of gynecology?

Clinical Obstetrics and Gynecology

Volumn 50, Issue 2, 2007, Pages 324-353

  Munro, Malcolm G ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER FOUNDATION HOSPITAL   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Endometrial ablation; Heavy menstrual bleeding; Hysterectomy; Menorrhagia; Uterine surgery

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; DANAZOL; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; IBUPROFEN; IRON; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; TRANEXAMIC ACID;

ACNE; ANOVULATION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CRYOABLATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG MECHANISM; ENDOMETRIUM; ENDOMETRIUM ABLATION; ENDOMETRIUM CARCINOMA; GASTROINTESTINAL SYMPTOM; HEMATOMETRA; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IMAGING; INTERMETHOD COMPARISON; IRON THERAPY; LEIOMYOMA; MASTECTOMY; MENSTRUATION DISORDER; METRORRHAGIA; MICROWAVE IRRADIATION; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; MYOMETRIUM; OILY SKIN; PATHOGENESIS; PATIENT SATISFACTION; RADIOFREQUENCY ABLATION; SIDE EFFECT; SKILL; THROMBOEMBOLISM; TRAINING; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVIX DISEASE; UTERUS; UTERUS BLEEDING; UTERUS PERFORATION; UTERUS TUMOR; VOICE CHANGE; WEIGHT GAIN;

CATHETER ABLATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYSTERECTOMY; INTRAUTERINE DEVICES, MEDICATED; MENORRHAGIA; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TREATMENT OUTCOME;

EID: 34249881911     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31804a82e2     Document Type: Article

References (185)

1. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143-1150.
2. Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003;98:697-702.
3. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28:289-294.
4. Donegan WL. Introduction to the history of breast cancer. In: Anonymous. Cancer of the Breast. Philadelphia: WB Saunders; 1995.
5. Cooper WA. The history of radical mastectomy. Ann Med Hist. 1941;36-54.
6. Lewison EF. The surgical treatment of breast cancer: an historical and collective review. Surgery. 1953;34:904-953.
7. Hager K. The Illustrated History of Surgery. New York: Bell; 1988.
8. Moore CH. On the influence of inadequate operations on the theory of cancer. Roy Med Chir Soc Lond. 1867;1:244-280.
9. Halstead WS. The results of operations for the cure of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Johns Hopkins Bull. 1894;4:297-305.
10. McWhirter R. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Br J Radiol. 1948;21:599-610.
11. Crile G Jr, Hoerr SO. Results of treatment of carcinoma of the breast by local excision. Surg Gynecol Obstet. 1971;132:780-782.
12. Temkin OT. Soranus' Gynecology. Baltimore: Johns Hopkins University Press; 1956.
13. Garrison FH. An Introduction to the History of Medicine. 4th ed. Philadelphia, PA: WB Saunders Co; 1929.
14. Langenbeck CJM. Geschichte einer von mir glucklich verichteten extirpation der ganger gebarmutter. Biblioth Chir Opth Hanover. 1817;1:557.
15. Ricci JV. The Development of Gynaecological Surgery and Instruments. Philadelphia, PA: Blakiston; 1949.
16. Burnham W. Extirpation of the uterus and ovaries for sarcomatous disease. Nelson's Am Lancet. 1854;8:147-151.
17. Garceau E. Vaginal hysterectomy as done in France. Am J Obstet Dis Women Child. 1895;31:305-346.
18. Green-Armytage VB. Vaginal hysterectomy: a new technique and follow-up of 500 consecutive operations for haemorrhage. J Obstet Gynaecol Br Emp. 1939;46:848-856.
19. Heaney NS. A series of 627 vaginal hysterectomies performed for benign disease with three deaths. Am J Obstet Gynecol. 1935;30:269-272.
20. Richardson EH. A simplified technique for abdominal panhysterectomy. Surg Gynecol Obstet. 1929;48:248-251.
21. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol. 2002;99:229-234.
22. Abel MH, Baird DT. The effect of 17 beta-estradiol and progesterone on prostaglandin production by human endometrium maintained in organ culture. Endocrinology. 1980;106:1599-1606.
23. Lumsden MA, Brown A, Baird DT. Prostaglandin production from homogenates of separated glandular epithelium and stroma from human endometrium. Prostaglandins. 1984;28:485-496.
24. Rees MC, Parry DM, Anderson AB, et al. Immunohistochemical localisation of cyclooxygenase in the human uterus. Prostaglandins. 1982;23:207-214.
25. Word RA, Kamm KE, Casey ML. Contractile effects of prostaglandins, oxytocin, and endothelin-1 in human myometrium in vitro: refractoriness of myometrial tissue of pregnant women to prostaglandins E2 and F2 alpha. J Clin Endocrinol Metab. 1992;75:1027-1032.
26. Woessner JF Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994;732:11-21.
27. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197-250.
28. McDonnell S, Wright JH, Gaire M, et al. Expression and regulation of stromelysin and matrilysin by growth factors and oncogenes. Biochem Soc Trans. 1994;22:58-63.
29. Lockwood CJ, Krikun G, Hausknecht VA, et al. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology. 1998;139:4607-4613.
30. Marbaix E, Vekemans M, Galant C, et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users. Hum Reprod. 2000;15(suppl 3):120-134.
31. Zhang J, Nie G, Jian W, et al. Mast cell regulation of human endometrial matrix metalloproteinases: a mechanism underlying menstruation. Biol Reprod. 1998;59:693-703.
32. Hofmann GE, Rao CV, De Leon FD, et al. Human endometrial prostaglandin E2 binding sites and their profiles during the menstrual cycle and in pathologic states. Am J Obstet Gynecol. 1985;151:369-375.
33. Smith SK, Abel MH, Kelly RW, et al. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1981;88:434-442.
34. Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol. 1986;93:974-978.
35. Rybo G. Plasminogen activators in the endometrium. II. Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood loss. Acta Obstet Gynecol Scand. 1966;45:429-450.
36. Gleeson N, Devitt M, Sheppard BL, et al. Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1993;100:768-771.
37. Gleeson NC, Buggy F, Sheppard BL, et al. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand. 1994;73:274-277.
38. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf). 1999;50:655-659.
39. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol. 2001;97:630-636.
40. Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrands disease or Factor XI deficiency. Br J Obstet Gynaecol. 1998;105:314-321.
41. Edlund M, Blomback M, von Schoultz B, et al. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol. 1996;53:234-238.
42. Day Baird D, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100-107.
43. Patterson-Keels LM, Selvaggi SM, Haefner HK, et al. Morphologic assessment of endometrium overlying submucosal leiomyomas. J Reprod Med. 1994;39:579-584.
44. Malcolm CE, Cumming DC. Does anovulation exist in eumenorrheic women? Obstet Gynecol. 2003;102:317-318.
45. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351:485-489.
46. Lusher JM. Screening and diagnosis of coagulation disorders. [Review] [25 refs]. Am J Obstet Gynecol. 1996;175(Pt 2):778-783.
47. Mohri H. High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. J Thromb Thrombolysis. 2002;14:255-257.
48. Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia. 1998;4:63-65.
49. Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia - expereince with seven cases. Haemophilia. 2004;10:477-482.
50. Farquhar CM, Lethaby A, Sowter M, et al. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol. 1999;181:525-529.
51. Ash SJ, Farrell SA, Flowerdew G. Endometrial biopsy in DUB. J Reprod Med. 1996;41:892-896.
52. Lu KH, Broaddus RR. Gynecological tumors in hereditary nonpolyposis colorectal cancer: we know they are common - now what? Gynecol Oncol. 2001;82:221-222.
53. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005;105:569-574.
54. Valle RF. Hysteroscopic evaluation of patients with abnormal uterine bleeding. Surg Gynecol Obstet. 1981;153:521-526.
55. Goldrath MH, Sherman AI. Office hysteroscopy and suction curettage: can we eliminate the hospital diagnostic dilatation and curettage? Am J Obstet Gynecol. 1985;152:220-229.
56. Stovall TG, Solomon SK, Ling FW. Endometrial sampling prior to hysterectomy. Obstet Gynecol. 1989;73:405-409.
57. Epstein E, Ramirez A, Skoog L, et al. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001;80:1131-1136.
58. Guido RS, Kanbour-Shakir A, Rulin MC, et al. Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J Reprod Med. 1995;40:553-555.
59. Emanuel MH, Verdel MJ, Wamsteker K, et al. A prospective comparison of transvaginal ultrasonography and diagnostic hysteroscopy in the evaluation of patients with abnormal uterine bleeding: clinical implications. Am J Obstet Gynecol. 1995;172:547-552.
60. Dueholm M, Lundorf E, Hansen ES, et al. Evaluation of the uterine cavity with magnetic resonance imaging, transvaginal sonography, hysterosonographic examination, and diagnostic hysteroscopy. Fertil Steril. 2001;76:350-357.
61. Breitkopf DM, Frederickson RA, Snyder RR. Detection of benign endometrial masses by endometrial stripe measurement in premenopausal women. Obstet Gynecol. 2004;104:120-125.
62. Bonilla-Musoles F, Simon C, Serra V, et al. An assessment of hysterosalpingosonography (HSSG) as a diagnostic tool for uterine cavity defects and tubal patency. J Clin Ultrasound. 1992;20:175-181.
63. Widrich T, Bradley LD, Mitchinson AR, et al. Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol. 1996;174:1327-1334.
64. Saidi MH, Sadler RK, Theis VD, et al. Comparison of sonography, sonohysterography, and hysteroscopy for evaluation of abnormal uterine bleeding. J Ultrasound Med. 1997;16:87-591.
65. Goldberg JM, Falcone T, Attaran M. Sonohysterographic evaluation of uterine abnormalities noted on hysterosalpingography. Hum Reprod. 1997;12:2151-2153.
66. Prevedourakis C, Loutradis D, Kalianidis C, et al. Hysterosalpingography and hysteroscopy in female infertility. Hum Reprod. 1994;9:2353-2355.
67. Togashi K, Nishimura K, Itoh K, et al. Adenomyosis: diagnosis with MR imaging. Radiology. 1988;166:111-114.
68. Fedele L, Bianchi S, Dorta M, et al. Transvaginal ultrasonography in the diagnosis of diffuse adenomyosis. Fertil Steril. 1992;58:94-97.
69. Vercellini P, Cortesi I, De Giorgi O, et al. Transvaginal ultrasonography versus uterine needle biopsy in the diagnosis of diffuse adenomyosis. Hum Reprod. 1998;13:2884-2887.
70. Brosens JJ, de Souza NM, Barker FG, et al. Endovaginal ultrasonography in the diagnosis of adenomyosis uteri: identifying the predictive characteristics. Br J Obstet Gynaecol. 1995;102:471-474.
71. Mark AS, Hricak H, Heinrichs LW, et al. Adenomyosis and leiomyoma: differential diagnosis with MR imaging. Radiology. 1987;163:527-529.
72. Popp LW, Schwiedessen JP, Gaetje R. Myometrial biopsy in the diagnosis of adenomyosis uteri. Am J Obstet Gynecol. 1993;169:546-549.
73. Janssen CA, Scholten PC, Heintz AP. Reconsidering menorrhagia in gynecological practice. Is a 30-year-old definition still valid? Eur J Obstet Gynecol Reprod Biol. 1998;78:69-72.
74. Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190:1216-1223.
75. Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol. 2004;190:1224-1229.
76. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J. 1970;4:214-216.
77. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995;102:401-406.
78. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996;313:579-582.
79. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand. 1988;67:645-648.
80. Cooke I, Lethaby A, Farquhar C. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;4:CD000249.
81. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thromboembolic complications. Thromb Haemost. 1993;70:238-240.
82. Rees MC, DiMarzo V, Tippins JR, et al. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol. 1987;113:291-295.
83. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2002;1:CD000400.
84. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol. 1990;30:353-356.
85. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol. 1993;169:1134-1139.
86. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;2:CD001016.
87. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998;105:592-598.
88. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97:690-694.
89. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164:879-883.
90. Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol. 1997;90:257-263.
91. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril. 2001;76:304-309.
92. Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004;104:1314-1321.
93. Soysal M, Soysal S, Ozer S. A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. Zentralbl Gynakol. 2002; 124:213-219.
94. Henshaw R, Coyle C, Low S, et al. A retrospective cohort study comparing microwave endometrial ablation with levonorgestrel-releasing intrauterine device in the management of heavy menstrual bleeding. Aust N Z J Obstet Gynaecol. 2002;42:205-209.
95. Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ. 1998;316:1122-1126.
96. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004;291:1456-1463.
97. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31:66-70.
98. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96:913-920.
99. Chimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol. 1980;87:1152-1158.
100. Bonduelle M, Walker JJ, Calder AA. A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgrad Med J. 1991;67:833-836.
101. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989;96:840-844.
102. Thomas EJ. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. Br J Obstet Gynaecol. 1996;103(suppl 14):18-21.
103. Cooper KG, Parkin DE, Garratt AM, et al. A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. Br J Obstet Gynaecol. 1997;104:1360-1366.
104. Cooper KG, Parkin DE, Garratt AM, et al. Two-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. Br J Obstet Gynaecol. 1999;106:258-265.
105. Cooper KG, Jack SA, Parkin DE, et al. Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. BJOG. 2001;108:1222-1228.
106. Kovac SR. Hysterectomy outcomes in patients with similar indications. Obstet Gynecol. 2000;95:787-793.
107. Mushinski M. Average charges for three types of hysterectomy procedures: United States, 1998. Stat Bull Metrop Insur Co. 2000;81:27-36.
108. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol. 2002;99:229-234.
109. Maresh MJ, Metcalfe MA, McPherson K, et al. The VALUE national hysterectomy study: description of the patients and their surgery. BJOG. 2002;109:302-312.
110. Summitt RL Jr, Stovall TG, Lipscomb GH, et al. Randomized comparison of laparoscopy-assisted vaginal hysterectomy with standard vaginal hysterectomy in an outpatient setting. Obstet Gynecol. 1992;80:895-901.
111. Kovac SR. Guidelines to determine the role of laparoscopically assisted vaginal hysterectomy. Am J Obstet Gynecol. 1998;178:1257-1263.
112. Lyons TL. Laparoscopic supracervical hysterectomy. A comparison of morbidity and mortality results with laparoscopically assisted vaginal hysterectomy. J Reprod Med. 1993;38:763-767.
113. Munro MG. Supracervical hysterectomy: ... a time for reappraisal. Obstet Gynecol. 1997;89:133-139.
114. Jones DE, Shackelford DP, Brame RG. Supracervical hysterectomy: back to the future? Am J Obstet Gynecol. 1999;180:513-515.
115. Scott JR, Sharp HT, Dodson MK, et al. Subtotal hysterectomy in modern gynecology: a decision analysis. Am J Obstet Gynecol. 1997;176:1186-1191; discussion 1191-1192.
116. Thakar R, Ayers S, Clarkson P, et al. Outcomes after total versus subtotal abdominal hysterectomy. N Engl J Med. 2002;347:1318-1325.
117. Learman LA, Summitt RL Jr, Varner RE, et al. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol. 2003;102:453-462.
118. Gimbel H, Zobbe V, Andersen BM, et al. Randomised controlled trial of total compared with subtotal hysterectomy with one-year follow up results. BJOG. 2003;110:1088-1098.
119. Carter JE, McCarus S. Time savings using the Steiner Morcellator in laparoscopic myomectomy. J Am Assoc Gynecol Laparosc. 1996;3:S6.
120. Zupi E, Zullo F, Marconi D, et al. Hysteroscopic endometrial resection versus laparoscopic supracervical hysterectomy for menorrhagia: a prospective randomized trial. Am J Obstet Gynecol. 2003;188:7-12.
121. Wilcox LS, Koonin LM, Pokras R, et al. Hysterectomy in the United States, 1988-1990. Obstet Gynecol. 1994;83:549-555.
122. Kjerulff KH, Langenberg PW, Rhodes JC, et al. Effectiveness of hysterectomy. Obstet Gynecol. 2000;95:319-326.
123. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol. 1994;83:556-565.
124. Brooks PG, Clouse J, Morris LS. Hysterectomy vs. resectoscopic endometrial ablation for the control of abnormal uterine bleeding. A cost-comparative study. J Reprod Med. 1994; 39:755-760.
125. Brooks SE, Mullins CD, Guo C, et al. Resource utilization for patients undergoing hysterectomy with or without lymph node dissection for endometrial cancer. Gynecol Oncol. 2002;85:242-249.
126. Broder MS, Kanouse DE, Mittman BS, et al. The appropriateness of recommendations for hysterectomy. Obstet Gynecol. 2000;95:199-205.
127. Bardenheuer FH. Elektrokoagulation der Uterusschleimhaut zur Behandlung klimakterischer Blutungen. Zentralblatt fur Gynakologie. 1937;4:209-211.
128. Cahan WG, Brockunier A Jr. Cryosurgery of the uterine cavity. Am J Obstet Gynecol. 1967;99:138-153.
129. Goldrath MH, Fuller TA, Segal S. Laser photovaporization of endometrium for the treatment of menorrhagia. Am J Obstet Gynecol. 1981;140:14-19.
130. DeCherney AH, DiamondMP, Lavy G, et al. Endometrial ablation for intractable uterine bleeding: hysteroscopic resection. Obstet Gynecol. 1987;70:668-670.
131. Vancaillie TG. Electrocoagulation of the endometrium with the ball-end resectoscope. Obstet Gynecol. 1989;74:425-427.
132. Vercellini P, Oldani S, DeGiorgi O, et al. Endometrial ablation with a vaporizing electrode in women with regular uterine cavity or submucous leiomyomas. J Am Assoc Gynecol Laparosc. 1996;3:S52.
133. Overton C, Hargreaves J, Maresh M. A national survey of the complications of endometrial destruction for menstrual disorders. The MISTLETOE study. Minimally Invasive Surgical Techniques - Laser, EndoThermal or Endorescetion. Br J Obstet Gynaecol. 1997;104:1351-1359.
134. Townsend DE, McCausland V, McCausland A, et al. Post-ablation-tubal sterilization syndrome. Obstet Gynecol. 1993;82:422-424.
135. McCausland AM, McCausland VM. Frequency of symptomatic cornual hematometra and postablation tubal sterilization syndrome after total rollerball endometrial ablation: a 10-year follow-up. Am J Obstet Gynecol. 2002;186:1274-1280; discussion 1280-1283.
136. Hare AA, Olah KS. Pregnancy following endometrial ablation: a review article. J Obstet Gynaecol. 2005;25:108-114.
137. Lo JS, Pickersgill A. Pregnancy after endometrial ablation: English literature review and case report. J Minim Invasive Gynecol. 2006;13:88-91.
138. Gannon MJ, Holt EM, Fairbank J, et al. A randomised trial comparing endometrial resection and abdominal hysterectomy for the treatment of menorrhagia. BMJ. 1991;303:1362-1364.
139. Sculpher MJ, Dwyer N, Byford S, et al. Randomised trial comparing hysterectomy and transcervical endometrial resection: effect on health related quality of life and costs two years after surgery. Br J Obstet Gynaecol. 1996;103:142-149.
140. Pinion SB, Parkin DE, Abramovich DR, et al. Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleeding. BMJ. 1994;309:979-983.
141. O'Connor H, Broadbent JA, Magos AL, et al. Medical Research Council randomised trial of endometrial resection versus hysterectomy in management of menorrhagia. Lancet. 1997;349:897-901.
142. Crosignani PG, Vercellini P, Apolone G, et al. Endometrial resection versus vaginal hysterectomy for menorrhagia: long-term clinical and quality-of-life outcomes. Am J Obstet Gynecol. 1997;177:95-101.
143. Lethaby A, Shepperd S, Cooke I, et al. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;2:CD000329.
144. Lethaby A, Hickey M, Garry R. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;4:CD001501.
145. Anonymous. A randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome at four years. Aberdeen Endometrial Ablation Trials Group. Br J Obstet Gynaecol. 1999;106:360-366.
146. Dickersin K, Munro MG, Langenberg P, et al. Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): Design and metnods. Control Clin Trials. 2003;24:591-609.
147. Sculpher M. The cost-effectiveness of preference-based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia. Health Econ. 1998;7:129-142.
148. Pooley AS, Ewen SP, Sutton CJ. Does transcervical resection of the endometrium for menorrhagia really avoid hysterectomy? Life table analysis of a large series. J Am Assoc Gynecol Laparosc. 1998;5:229-235.
149. Seidman DS, Bitman G, Mashiach S, et al. The effect of increasing age on the outcome of hysteroscopic endometrial resection for management of dysfunctional uterine bleeding. J Am Assoc Gynecol Laparosc. 2000;7:115-119.
150. McCausland V, McCausland A. The response of adenomyosis to endometrial ablation/resection. Hum Reprod Update. 1998;4:350-359.
151. Tresserra F, Grases P, Ubeda A, et al. Morphological changes in hysterectomies after endometrial ablation. Hum Reprod. 1999;14:1473-1477.
152. Browne DS. Endometrial resection - a comparison of techniques. Aust N Z J Obstet Gynaecol. 1996;36:448-452.
153. Eskandar MA, Vilos GA, Aletebi FA, et al. Hysteroscopic endometrial ablation is an effective alternative to hysterectomy in women with menorrhagia and large uteri. J Am Assoc Gynecol Laparosc. 2000;7:339-345.
154. Sowter MC, Lethaby A, Singla AA. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding. Cochrane Database Syst Rev. 2002;3:CD001124.
155. Marsh F, Thewlis J, Duffy S. Therma-choice endometrial ablation in the outpatient setting, without local anesthesia or intravenous sedation: a prospective cohort study. Fertil Steril. 2005;83:715-720.
156. Meyer WR, Walsh BW, Grainger DA, et al. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol. 1998;92:98-103.
157. Grainger DA, Tjaden BL, Rowland C, et al. Thermal balloon and rollerball ablation to treat menorrhagia: two-year results of a multicenter, prospective, randomized, clinical trial. J Am Assoc Gynecol Laparosc. 2000;7:175-179.
158. Loffer FD. Three-year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2001;8:48-54.
159. Loffer FD, Grainger D. Five-year follow-up of patients participating in a randomized trial of uterine balloon therapy versus rollerball ablation for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002;9:429-435.
160. Richart RM, das Dores GB, Nicolau SM, et al. Histologic studies of the effects of circulating hot saline on the uterus before hysterectomy. J Am Assoc Gynecol Laparosc. 1999;6:269-273.
161. Corson SL. A multicenter evaluation of endometrial ablation by Hydro Therm-Ablator and rollerball for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2001;8:359-367.
162. Goldrath MH. Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 years after treatment. J Am Assoc Gynecol Laparosc. 2003;10:505-511.
163. Duleba AJ, Heppard MC, Soderstrom RM, et al. Randomized study comparing endometrial croyoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. J Am Assoc Gynecol Laparosc. 2003;10:17-26. (Abstract).
164. Townsend DE, Duleba AJ, Wilkes MM. Durability of treatment effects after endometrial cryoablation versus rollerball electroablation for abnormal uterine bleeding: two-year results of a multicenter randomized trial. Am J Obstet Gynecol. 2003;188:699-701.
165. Gallinat A, Nugent W. NovaSure impedance-controlled system for endometrial ablation. J Am Assoc Gynecol Laparosc. 2002;9:283-289.
166. Rosenbaum SP, Fried M, Munro MG. Endometrial hydrothermablation: a comparison of short-term clinical effectiveness in patients with normal endometrial cavities and those with intracavitary pathology. J Minim Invasive Gynecol. 2005;12:144-149.
167. Cooper J, Gimpelson R, Laberge P, et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002;9:418-428.
168. Bongers MY, Bourdrez P, Mol BW, et al. Randomised controlled trial of bipolar radio-frequency endometrial ablation and balloon endometrial ablation. BJOG. 2004;111:1095-1102.
169. Laberge PY, Sabbah R, Fortin C, et al. Assessment and comparison of intraoperative and postoperative pain associated with NovaSure and ThermaChoice endometrial ablation systems. J Am Assoc Gynecol Laparosc. 2003;10:223-232.
170. Cooper KG, Bain C, Parkin DE. Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet. 1999;354:1859-1863.
171. Bain C, Cooper KG, Parkin DE. Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstet Gynecol. 2002;99:983-987.
172. Cooper JM, Anderson TA, Fortin CA, et al. Microwave endometrial ablation vs. rollerball electroablation for menorrhagia: a multicenter randomized trial. J Am Assoc Gynecol Laparosc. 2004;11:394-403. (Abstract).
173. Gurtcheff SE, Sharp HT. Complications associated with global endometrial ablation: the utility of the MAUDE database. Obstet Gynecol. 2003;102:1278-1282.
174. Hawe J, Abbott J, Hunter D, et al. A randomised controlled trial comparing the Cavaterm™ endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. Br J Obstet Gynaecol. 2003;110:350-357. (Abstract).
175. Garside R, Stein K, Wyatt K, et al. A cost-utility analysis of microwave and thermal balloon endometrial ablation techniques for the treatment of heavy menstrual bleeding. BJOG. 2004;111:1103-1114.
176. Cooper KG, Bain C, Lawrie L, et al. A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium; follow up at a minimum of five years. BJOG. 2005;112:470-475.
177. Glasser MH, Zimmerman JD. The HydroThermAblator system for management of menorrhagia in women with submucous myomas: 12- to 20-month follow-up. J Am Assoc Gynecol Laparosc. 2003;10:521-527.
178. Sabbah R, Desaulniers G. Use of the Novasure impedance controlled endometrial ablation system in women with intracavitary disease: twelve-month follow-up results of a prospective, single arm clinical study. J Min Invasive Gynecol. 2006;13:467-471.
179. Yang JZ, Van Vugt DA, Kennedy JC, et al. Evidence of lasting functional destruction of the rat endometrium after 5-aminolevulinic acid-induced photodynamic ablation: prevention of implantation. Am J Obstet Gynecol. 1993;168:995-1001.
180. Bhatta N, Anderson RR, Flotte T, et al. Endometrial ablation by means of photodynamic therapy with photofrin II. Am J Obstet Gynecol. 1992;167:1856-1863.
181. Donnez J, Polet R, Rabinovitz R, et al. Endometrial laser intrauterine thermotherapy: the first series of 100 patients observed for 1 year. Fertil Steril. 2000;74:791-796.
182. Perino A, Castelli A, Cucinella G, et al. A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertil Steril. 2004;82:731-734.
183. Corson SL, Brill AI, Brooks PG, et al. One-year results of the vesta system for endometrial ablation. J Am Assoc Gynecol Laparosc. 2000;7:489-497.
184. Kucuk M, Okman TK. Intrauterine instillation of trichloroacetic acid is effective for the treatment of dysfunctional uterine bleeding. Fertil Steril. 2005;83:189-194.
185. Valle RF, Baggish MS. Endometrial carcinoma after endometrial ablation: high-risk factors predicting its occurrence. Am J Obstet Gynecol. 1998;179:569-572.